April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Yüksel Ürün: Ivonescimab vs pembrolizumab in PD-L1 positive NSCLC
Mar 8, 2025, 09:01

Yüksel Ürün: Ivonescimab vs pembrolizumab in PD-L1 positive NSCLC

Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared a post on X about recent paper by Anwen Xiong et al., titled “Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China” published on The Lancet.

Authors: Anwen Xiong, Lei Wang, Jianhua Chen, Lin Wu, Baogang Liu, Jun Yao, Hua Zhong, Jie Li, Ying Cheng, Yulan Sun, Hui Ge, Jifang Yao, Qin Shi, Ming Zhou, Bolin Chen, Zhengxiang Han, Jinliang Wang, Qing Bu, Yanqiu Zhao, Junqiang Chen, Caicun Zhou

Yüksel Ürün: Ivonescimab vs pembrolizumab in PD-L1 positive NSCLC

“New study alert!

Ivonescimab hit 11.1m PFS vs 5.8m with pembrolizumab in PD-L1+ NSCLC. Promisin results that might shift treatment options!”